VJHemOnc is committed to improving our service to you

ASH 2019 | Interim results for BCMA T-cell engager CC-93269 in RRMM

VJHemOnc is committed to improving our service to you

Luciano Costa

Luciano Costa, MD, PhD, University of Alabama at Birmingham, Birmingham, AL, presents the interim results of the first clinical study of the bispecific BCMA/CD3 T-cell engager CC-93269 in patients with relapsed/refractory multiple myeloma (CC-93269-MM-001; NCT03486067). This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter